Clinical Trial

A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

Study acronym: STOP-PC
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated August 13, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical study is to compare the efficacy and safety of OT-101 in combination with mFOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to mFOLFIRINOX alone in patients with advanced and unresectable or metastatic pancreatic cancer.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-10-05; most recent amendment 2024-08-10.
Status change: Not Yet Recruiting → Recruiting 2024-05-17
Trial Details
NCT Number NCT06079346
Lead Sponsor Oncotelic Inc.
Conditions Pancreatic Ductal Adenocarcinoma
Enrollment 455 participants
Start Date 2024-05-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-13